Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Osteoporosis Reports
Erschienen in: Current Osteoporosis Reports 4/2014

01.12.2014 | Orthopedic Management of Fractures (D Little and T Miclau, Section Editors)

Atypical Femur Fractures: A Review

verfasst von: Wesley H. Bronson, I. David Kaye, Kenneth A. Egol

Erschienen in: Current Osteoporosis Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Bisphosphonates are one of the most commonly prescribed medications for the treatment of osteoporosis. Their use has greatly decreased the number of osteoporosis-related vertebral and nonvertebral fractures. Recently, however, a relationship between long-term bisphosphonate use and subtrochanteric and femoral shaft fractures has been elucidated. These low-energy fractures, termed atypical femur fractures, exhibit unique characteristics in their pathophysiology, presentation, and radiographic appearance compared with more traditional high-energy femur fractures. Here we provide a review based on the most recent literature of the pathophysiology, presentation, evaluation, and management of these fractures. Despite an abundance of literature, atypical femur fractures remain difficult to treat, and surgeons must be aware of the tricks and complications associated with their management.
Literatur
1.
Kanis JA. Assessment of Osteoporosis at the Primary Health-Care Level, WHO Technical Report. Sheffield, UK:WHO Scientific Group, World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; 2007.
2.
Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep. 2010;8:34–9.PubMedCrossRef
3.
Poor G, Atkinson EJ, O’Fallon WM, Melton LJ. Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res. 1995;319:260–5.PubMed
4.
Melton III LJ. Adverse outcomes of osteoporotic fractures in the general population. J Bone Min Res. 2003;18:1139–41.CrossRef
5.
Dell R, Greene D. Is osteoporosis diseases management cost effective? Curr Osteoporos Rep. 2010;8:49–55.PubMedCrossRef
6.
Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761–7.PubMedCrossRef
7.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22.PubMedCrossRef
8.
Unnanuntana A, Saleh A, Mensah KA, Kleimeyer JP, Lane JM. Atypical femoral fractures: what do we know about them? AAOS Exhibit Selection. J Bone Joint Surg Am. 2013;95:e8 1–13.CrossRef
9.
De Das S, Setiobudi T, Shen L. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg (Br). 2010;92:679–86.CrossRef
10.
Girgis CM, Seibel MJ. Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures. Bone. 2011;48:963–5.PubMedCrossRef
11.
Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24:1736–40.PubMedCrossRef
12.
Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–301.PubMedCrossRef
13.
Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009;91:2556–61.PubMedCrossRef
14.
Hollick RJ, Reid DM. Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties. Menopaus Int. 2011;17:66–72.
15.
Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346–50.PubMedCrossRef
16.
Yoon RS, Hwang JS, Beebe KS. Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern? J Bone Joint Surg (Br). 2011;93:1289–95.CrossRef
17.
Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94.PubMedCrossRef
18.••
Shane E, Burr D, Abrahamsen B, Adler R, Brown T, Cheung A, et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23. Reviews the latest evidence related to the epidemiology, pathogenesis, and medical management of atypical femur fractures, as well as sets an updated, accepted definition. PubMedCrossRef
19.
Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int. 2011;22:2951–61.PubMedCrossRef
20.
Watts N, Diab D. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555–65.PubMedCrossRef
21.
Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613–20.PubMedCrossRef
22.
Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93:2948–52.PubMedCrossRef
23.
Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int. 2009;85:37–44.PubMedCrossRef
24.
Wang Z, Bhattacharyya T. Trends in the incident of subtrochanteric fragility fractures and bisphosphonate use among the US elderly. J Bone Miner Res. 2011;26:553–60.PubMedCrossRefPubMedCentral
25.••
Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305:783–9. This is a case-control study that demonstrates the association between prolonged bisphosphonate use and the increased risk of atypical femur fractures. PubMedCrossRef
26.
Schilcher J, Michaelson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364:1728–37.PubMedCrossRef
27.
Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone. 2011;48(5):966–71.PubMedCrossRef
28.•
Marcano A, Taormina D, Egol KA, Peck V, Tejwani NC. Are race and sex associated with the occurrence of atypical femoral fractures? Clin Orthop Relat Res. 2014;472(3):1020–7. Review of prospectively collected demographic data demonstrating the increased risk of woman, Asians and Hispanics for suffering an atypical femur fracture in the setting of bisphosphonate use. PubMedCrossRef
29.
Beaudouin-Bazire C, Dalmas N, Bourgeois J, Babinet A, Anract P, Chantelot C, et al. Real frequency of ordinary and atypical sub-trochanteric and diaphyseal fractures in France based on X-rays and medical file analysis. Joint Bone Spine. 2013;80(2):201–5.PubMedCrossRef
30.
Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27(12):2544–50.PubMedCrossRef
31.
Lo JC, Huang SY, Lee GA, Khandewal S, Provus J, Ettinger B, et al. Clinical correlates of atypical femoral fracture. Bone. 2012;51(1):181–4.PubMedCrossRef
32.
Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010;47(2):169–80.PubMedCrossRef
33.
Wang K, Moaveni A, Dowrick A, et al. Alendronate-associated femoral insufficiency fractures and femoral stress reactions. J Orthop Surg. 2011;19(1):89–92.
34.
Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of sub- trochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224–31.PubMedCrossRef
35.
Clement DB, Ammann W, Taunton JE, et al. Exercise-induced stress injuries to the femur. Int J Sports Med. 1993;14:347–52.PubMedCrossRef
36.
37.
Chan SS, Rosenberg ZS, Chan K, et al. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. Am J Roentgenol. 2010;194:1581–6.CrossRef
38.
Perret MC, Foulner D, Glennon DA. Subtrochanteric fractures in patients on long term bisphosphonate therapy. J Surg Radiol. 2011;2:294–302.
39.
Aghbari MS, Honig S, Egol KA. Diagnosis and treatment of bisphosphonate-induced atypical femoral fractures. Aging Health. 2013;9(4):451–7.CrossRef
40.
Grey A, Bolland M, Horne A, Gamble G, Reid IR. Prolonged antiresorptive activity of zolendronate: a randomized, controlled trial. J Bone Miner Res. 2010;25(10):2251–5.PubMedCrossRef
41.
Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of Alendronate. Clin Pharmacokinet. 1999;36(5):315–28.PubMedCrossRef
42.
Markman LH, Allison MB, Rosenberg ZS, Vieira RL, Babb JS, Tejwani NC, et al. A retrospective review of patients with atypical femoral fractures while on long-term bisphosphonates: including pertinent biochemical and imaging studies. Endocr Pract. 2013;21:1–23.
43.
Gehrig L, Lane J, O’Connor MI. Osteoporosis: management and treatment strategies for orthopaedic surgeons. J Bone Joint Surg Am. 2008;90(6):1362–74.PubMed
44.
Ross CA, Taylor CL, Yaktine AL, Del Valle HB. Dietary reference intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2011. p. 1132.
45.
Alcantara-Martos T, Delgado-Martinez AD, Vega MV, Carrscal MT, Munuera-Martinez L. Effect of vitamin C on fracture healing in elderly Osteogenic Disorder Shionogi rats. J Bone Joint Surg (Br). 2007;89(3):402–7.CrossRef
46.
Sarisozen B, Durak K, Dincer G, Bilgen OF. The effects of vitamins E and C on fracture healing in rats. J Int Med Res. 2002;30(3):309–13.PubMedCrossRef
47.
Andreassen TT, Fledelius C, Ejersted C, Oxlund H. Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone. Acta Orthop Scand. 2001;72(3):304–7.PubMedCrossRef
48.
Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. 1999;14(6):960–8.PubMedCrossRef
49.
Skripitz R, Andreassen TT, Aspenberg P. Parathyroid hormone (1-34) increases the density of rat cancellous bone in a bone chamber. A dose-response study. J Bone Joint Surg (Br). 2000;82(1):138–41.CrossRef
50.
Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003;18(3):539–43.PubMedCrossRef
51.
52.
Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93(17):1583–7.PubMedCrossRef
53.
Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double‐blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25:404–14.PubMedCrossRef
54.
55.
56.
57.
58.
Chiang CY, Zebaze RM, Ghasem-Zadeh A, Luliano-Burns S, Hardidge A, Seeman E. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone. 2013;52:360–5.PubMedCrossRef
59.
Lin EA, Liu CJ, Monroy A, Khurana S, Egol KA. Prevention of atrophic nonunion by the systemic administration of parathyroid hormone (PTH 1-34) in an experimental animal model. J Orthop Trauma. 2012;26(12):719–23.PubMedCrossRef
60.••
Banffy MB, Vrahas MS, Ready JE, Abraham JA. Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures. Clin Orthop Relat Res. 2011;469:2028–34. This is a retrospective review of patients with atypical femur fractures comparing nonoperative management with prophylactic operative fixation. The study demonstrates a high rate of fracture completion and displacement with nonoperative treatment. PubMedCrossRefPubMedCentral
61.
Ha YC, Cho MR, Park KH, Kim SY, Koo KH. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res. 2010;468(12):3393–8.PubMedCrossRefPubMedCentral
62.•
Egol KA, Park JH, Prensky C, Rosenberg ZS, Peck V, Tejwani NC. Surgical treatment improves clinical and functional outcomes for patients who sustain incomplete bisphosphonate-related femur fractures. J Orthop Trauma. 2013;27:331–5. This is a retrospective review that compares nonoperative and operative management of incomplete atypical femur fractures. The results indicate faster healing and improved pain scores in patients treated operatively. PubMedCrossRef
63.
Prasarn ML, Ahn J, Helfet DL, Lane JM, Lorich DG. Bisphosphonate-associated femur fractures have high complication rates with operative fixation. Clin Orthop Relat Res. 2012;470:2295–301.PubMedCrossRefPubMedCentral
64.
Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res. 2002;17(12):2237–46.PubMedCrossRef
65.
Desai PA, Vyas PA, Lane JM. Atypical femoral fractures: a review of the literature. Curr Osteoporos Rep. 2013;11:179–87.PubMedCrossRef
66.
Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma. 2011;71(1):186–90.PubMedCrossRef
Metadaten
Titel
Atypical Femur Fractures: A Review
verfasst von
Wesley H. Bronson
I. David Kaye
Kenneth A. Egol
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Current Osteoporosis Reports / Ausgabe 4/2014
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-014-0239-7

Weitere Artikel der Ausgabe 4/2014

Current Osteoporosis Reports 4/2014 Zur Ausgabe

Therapeutics and Medical Management (E Shane and RA Adler, Section Editors)

Osteoporosis Diagnosis in Men: The T-Score Controversy Revisited

Skeletal Development (E Schipani and E Zelzer, Section Editors)

Extracellular Matrix and Developing Growth Plate

Imaging (T Lang and F Wehrli, Section Editors)

Imaging of the Muscle-Bone Relationship

Imaging (T Lang and F Wehrli, Section Editors)

Imaging of Site Specific Bone Turnover in Osteoporosis Using Positron Emission Tomography

Imaging (T Lang and F Wehrli, Section Editors)

Vibrational Spectroscopic Imaging for the Evaluation of Matrix and Mineral Chemistry

Skeletal Development (E Schipani and E Zelzer, Section Editors)

microRNAs in Cartilage Development, Homeostasis, and Disease

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise